

		8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00	
Kobe Portopia Hotel	South Wing	No. 1 (1F Portopia Hall)	Symposium 1 Emerging treatment for B cell lymphoma Chairs : Koji Izutsu, Lorenzo Falchi				Presidential Symposium Therapeutic strategy for AML with FLT3 mutations Chair : Hitoshi Kiyoi	ASH Special Lecture Chair : Koichi Akashi Speaker : Belinda Avalos	Opening/Award Ceremony	Presidential Lecture	JSH-ASH Joint Symposium Recent advances in molecular pathogenesis of acute leukemia Chairs : Takahiro Yamauchi, Belinda Avalos			JSH Business Meeting
	Main Building	No. 2 (B1F Kairaku 1)	EL1-2-1	EL1-2-2	EL1-2-3	EL1-2-4	EL1-2-5	IS1-2 BeOne Medicines Japan	LS1-2 Meiji Seika Pharma Co., Ltd.		EL1-2-6	EL1-2-7	EL1-2-8	ES1-2 Daiichi Sankyo Medical Affairs
		No. 3 (B1F Kairaku 3)	EL1-3-1	EL1-3-2	EL1-3-3	EL1-3-4	EL1-3-5		LS1-3 Johnson & Johnson		EL1-3-6	EL1-3-7	EL1-3-8	ES1-3 Sanofi K.K.
		No. 4 (B1F Waraku)	Symposium 2 Energy acquisition in hematopoietic stem cells Chairs : Ayako Nakamura-Ishizu, Hideyo Hirai						LS1-4 Pharming Group N.V.		Symposium 3 Exploring the complement system in hematology: biological insights and emerging therapeutic prospects Chairs : Yasutaka Ueda, Naoshi Obara			ES1-4 Asahi Kasei Pharma Corporation
	South Wing	No. 5 (B1F Sapphire)												
		No. 6 (B1F Topaz)												
		No. 7 (B1F Emerald)												
		No. 8 (B1F Diamond)												
Kobe International Conference Center		No. 9 (1F Main Hall)	O1-9A AML: Basic 1 Chair : Yoshikane Kikushige	O1-9B AML: Clinical 1 Chair : Hisayuki Yokoyama			LS1-9 CHUGAI PHARMACEUTICAL CO.,LTD.			O1-9C CML: Clinical Trial Chair : Chikashi Yoshida	O1-9D	ES1-9 Nippon Shinyaku Co., Ltd.		
	No. 10 (3F International Conference Room 301)	EL1-10-1	EL1-10-2	EL1-10-3	EL1-10-4	EL1-10-5	LS1-10 Pfizer Japan Inc.		EL1-10-6	EL1-10-7	EL1-10-8	ES1-10 Pfizer Japan Inc.		
	No. 11 (4F 401+402)	O1-11A	O1-11B				LS1-11 Sobi Japan		O1-11C	O1-11D	ES1-11 Takeda Pharmaceutical Company Limited			
	No. 12 (4F 403)						LS1-12 Mitsubishi Tanabe Pharma Corporation				ES1-12 CHUGAI PHARMACEUTICAL CO.,LTD.			
	No. 13 (5F 501)	O1-13A CAR-T: Clinic 1 Chair : Yoshihiro Inamoto	O1-13B			LS1-13 Novo Nordisk Pharma Ltd.			O1-13C	O1-13D	ES1-13 Novartis Pharma K.K.			
	No. 14 (5F 502)	SETP1 Cellular Immunotherapy for Hematological Malignancies	SETP2 Molecular Pathogenesis of Multiple Myeloma			LS1-14 Incyte Biosciences Japan G.K.			O1-14C Platelet Disorder/Thrombosis Chair : Hirokazu Kashiwagi	O1-14D Coagulation Disorder/Others Chair : Akira Katsumi	ES1-14 ONO PHARMACEUTICAL CO., LTD.			
	No. 15 (5F 504+505)	O1-15A Infections/Others Chair : Shigeo Fuji	O1-15B			LS1-15 Shionogi & Co.,Ltd.			O1-15C	O1-15D	ES1-15 Sumitomo Pharma Co.,Ltd.			
	Kobe International Exhibition Hall	No.2 Building	No. 16 (3F 3A Meeting Room)	O1-16A	O1-16B			LS1-16 DAIICHI SANKYO COMPANY, LIMITED.			O1-16C	O1-16D	ES1-16 CHUGAI PHARMACEUTICAL CO.,LTD.	
No.1 Building		No. 17 (2F 2A Meeting Room)	O1-17A	O1-17B			LS1-17 AstraZeneca K.K.			O1-17C T/NK/HL: Genome Analysis and Real-world Data Chair : Akinao Okamoto	O1-17D T/NK/HL: Clinical Trials and Disease Analysis Chair : Yasuhito Suehara	ES1-17 Medical Affairs Division, Johnson & Johnson		
		No. 18 (2F Exhibition Hall B)	O1-18A	O1-18B			LS1-18 Sanofi K.K.			O1-18C DLBCL: Bispecific Antibody/PCNSL/Others Chair : Hiroyuki Takahashi	O1-18D	ES1-18 Bristol Myers Squibb K.K.		
No. 19 (2F Exhibition Hall A)		O1-19A Clinical Trials in Multiple Myeloma 1 Chair : Hiroshi Handa	O1-19B Clinical Trials in Multiple Myeloma 2 Chair : Shigeki Ito			LS1-19 GlaxoSmithKline K.K.			O1-19C Biomarkers and Prognostic Factors in Multiple Myeloma and Related Disease Chair : Daisuke Ogiya	O1-19D	ES1-19 GlaxoSmithKline K.K.			
		8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00	

		8 : 00		9 : 00		10 : 00		11 : 00		12 : 00		13 : 00		14 : 00		15 : 00		16 : 00		17 : 00		18 : 00		19 : 00	
Kobe Portopia Hotel	South Wing	No. 1 (1F Portopia Hall)				Symposium 4 Cutting edge of genetic basis and current immune therapies in multiple myeloma Chairs : Shinsuke Iida, Yawara Kawano				Special Lecture 1 Chair : Yasushi Miyazaki Speaker : Hartmut Döhner				Plenary Session Chairs : Seishi Ogawa, Toshihiro Miyamoto		Special Lecture 2 Chair : Kinuko Mitani Speaker : Stephanie Lee		JSH-EHA Joint Symposium Development of novel therapies to prevent post-transplant recurrence Chairs : Naoyuki Uchida, Konstanze Döhner							
	Main Building	No. 2 (B1F Kairaku 1)		MS2-2 Genmab KK, Medical Affairs / AbbVie GK, Medical		EL2-2-1		EL2-2-2		EL2-2-3		IS2-2 Medical Affairs Division, Alexion Pharma G.K.		LS2-2 Astellas Pharma Inc.				EL2-2-4		EL2-2-5		EL2-2-6		ES2-2 Novartis Pharma K.K.	
		No. 3 (B1F Kairaku 3)		MS2-3 Bristol Myers Squibb K.K.		O2-3A ALL: Basic 1 Chair : Takeshi Inukai				O2-3B ALL: Clinical Chair : Fumihiko Hayakawa				LS2-3 Gilead Sciences K.K.				O2-3C				O2-3D		ES2-3 Bristol Myers Squibb K.K.	
		No. 4 (B1F Waraku)		MS2-4 DAIICHI SANKYO COMPANY, LIMITED.		Women Physicians Career Symposium Mentorship and Women Physicians' Career Advancement Chairs : Junko Takita, Motoko Yamaguchi								LS2-4 ONO PHARMACEUTICAL CO., LTD.				O2-4C MDS: Basic 1 Chair : Yotaro Ochi		O2-4D MDS: Clinical 1 Chair : Yosuke Masamoto		ES2-4 Pfizer Japan Inc.		Reception for all the participants Kobe Portopia Hotel South Wing 1F Ohwara (19 : 30~)	
	No. 5 (B1F Sapphire)		MS2-5 BeOne Medicines Japan		O2-5A Hemolytic Anemia 1 Chair : Jun-ichi Nishimura				O2-5B				LS2-5 Minophagen Pharmaceutical Co., Ltd.				O2-5C		O2-5D		ES2-5 Sobi Japan / Asahi Kasei Pharma Corporation				
	No. 6 (B1F Topaz)												LS2-6 Takeda Pharmaceutical Company Limited				O2-6C		O2-6D		ES2-6 CHUGAI PHARMACEUTICAL CO.,LTD./ Nippon Shinyaku Co., Ltd.				
	South Wing	No. 7 (B1F Emerald)		MS2-7 Sanofi K.K.		EL2-7-1		EL2-7-2		EL2-7-3				LS2-7 Eisai Co., Ltd.				EL2-7-4		EL2-7-5		EL2-7-6		ES2-7 Takeda Pharmaceutical Company Limited	
		No. 8 (B1F Diamond)												LS2-8 PharmaEssentia Japan						Asian Joint Panel Discussion Novel therapeutic approaches for refractory hematological malignancies Chairs : Ritsuro Suzuki, Seok-Jin Kim				ES2-8 ONO PHARMACEUTICAL CO., LTD.	
Kobe International Conference Center		No. 9 (1F Main Hall)		MS2-9 Novartis Pharma K.K.		O2-9A DLBCL: CAR-T Chair : Nobuhiko Nakamura				O2-9B DLBCL: Prognostic Factors 1 Chair : Kana Miyazaki				LS2-9 Novartis Pharma K.K.				Special Symposium				ES2-9 Nihon Servier Co., Ltd.			
		No. 10 (3F International Conference Room 301)		MS2-10 CHUGAI PHARMACEUTICAL CO., LTD.		EL2-10-1		EL2-10-2		EL2-10-3				LS2-10 Bristol Myers Squibb K.K.				EL2-10-4		EL2-10-5		EL2-10-6		ES2-10 GlaxoSmithKline K.K.	
		No. 11 (4F 401+402)		MS2-11 Takeda Pharmaceutical Company Ltd. Japan Medical Office		O2-11A				O2-11B				LS2-11 KISSEI PHARMACEUTICAL CO., LTD.				O2-11C B-cell Lymphoma: Basic Research Chair : Noriaki Yoshida		O2-11D		ES2-11 Takeda Pharmaceutical Company Limited			
		No. 12 (4F 403)												LS2-12 Therakos Japan K.K.										ES2-12 MSD K.K.	
		No. 13 (5F 501)		MS2-13 Pfizer Japan Inc. Medical Affairs		JSH-EHA Travel Grant Awardee's Session in JSH2025 Chairs : Seishi Ogawa, Naoki Hosen						LS2-13 Recordati Rare Diseases Japan K.K.				O2-13C		O2-13D				ES2-13 Novartis Pharma K.K.			
		No. 14 (5F 502)		MS2-14 Sumitomo Pharma Co.,Ltd		SETP3 Molecular Targets for the Treatment of AML				SETP4 Novel Therapeutic Strategies for Malignant Lymphoma				LS2-14 Fuji Pharma Co., Ltd.				O2-14C		O2-14D CML: Basic and Translational Research Chair : Kazunori Murai				ES2-14 Sanofi Rare Blood Disorders Medical	
		No. 15 (5F 504+505)		MS2-15 Meiji Seika Pharma Co., Ltd.		O2-15A Cell Therapy: Basic 1 Chair : Yusuke Ito				O2-15B				LS2-15 SymBio Pharmaceuticals Ltd.				O2-15C		O2-15D Bone Marrow Failure: Clinical Study 2 Chair : Kohei Hosokawa				ES2-15 Kyowa Kirin Co., Ltd.	
		Kobe International Exhibition Hall	No.2 Building	No. 16 (3F 3A Meeting Room)		MS2-16 Johnson & Johnson		O2-16A				O2-16B				LS2-16 BeOne Medicines Japan				O2-16C AML: Basic 2 Chair : Daichi Inoue		O2-16D AML: Clinical 2 Chair : Kazuaki Yokoyama			
No. 17 (2F 2A Meeting Room)				MS2-17 Gilead Sciences K.K.		O2-17A				O2-17B Regulatory Mechanisms of Hematopoiesis Chair : Kenichi Miharada				LS2-17 Asahi Kasei Pharma Corporation				O2-17C		O2-17D AML: Basic 4 Chair : Naoko Hosono				ES2-17 Johnson & Johnson	
No.1 Build.	No. 18 (2F Exhibition Hall B)		MS2-18 ASAHI KASEI Pharma Corporation		O2-18A AML: Clinical 3 Chair : Satoshi Wakita				O2-18B				LS2-18 AbbVie GK				O2-18C AML: Clinical 5 Chair : Junichiro Yuda		O2-18D AML: Clinical 6 Chair : Toru Kiguchi				ES2-18 Otsuka Pharmaceutical Co., Ltd.		
	Poster (No.1 Build. 2F Exhibition Hall A / No.3 Build. 1F Exhibition Hall)				Poster Mounting (8 : 00~11 : 00)				Poster Viewing (11 : 00~18 : 10)														Poster Discussion (18 : 10~19 : 10)		
		8 : 00		9 : 00		10 : 00		11 : 00		12 : 00		13 : 00		14 : 00		15 : 00		16 : 00		17 : 00		18 : 00		19 : 00	

		8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00
Kobe Portopia Hotel	South Wing	No. 1 (1F Portopia Hall)		Symposium 5 Development of novel therapies for myeloproliferative neoplasms Chairs : Yuka Sugimoto, Tomoiku Takaku			JSH Award Lecture Chair : Yuka Sugimoto, Tomoiku Takaku Speaker : Konstanze Döhner		Symposium 8 Importance of T cell fitness in cancer immunotherapy Chairs : Maiko Matsushita, Zinaida Good				
	Main Building	No. 2 (B1F Kairaku 1)	MS3-2 Sanofi K.K.	EL3-2-1	EL3-2-2	EL3-2-3		LS3-2 argenx Japan K.K.	O3-2C	O3-2D			
		No. 3 (B1F Kairaku 3)	MS3-3 Gilead Sciences K.K.	O3-3A Multiple Myeloma: Basic Research 1 Chair : Yoichi Imai		O3-3B		LS3-3 Sumitomo Pharma Co., Ltd.	O3-3C	O3-3D			
		No. 4 (B1F Waraku)	MS3-4 CHUGAI PHARMACEUTICAL CO., LTD.	Symposium 6 Risk of thrombosis in unexpected places Chairs : Katsue Suzuki-Inoue, Keiji Nogami				LS3-4 Kyowa Kirin Co., Ltd.	O3-4C MPN: Clinical 2 Chair : Kazuhiko Ikeda	O3-4D			
	South Wing	No. 5 (B1F Sapphire)	MS3-5 BeOne Medicines Japan	O3-5A	O3-5B			LS3-5 MSD K.K.	Public Symposium				
		No. 6 (B1F Topaz)	MS3-6 Otsuka Pharmaceutical Co., Ltd. Medical Affairs	O3-6A AML: Basic 5 (Drug Resistance/Therapeutic Target) Chair : Hiroyoshi Kunimoto	O3-6B AML: Basic 6 Chair : Fumihiko Ishikawa			LS3-6 Otsuka Pharmaceutical Co., Ltd.					
		No. 7 (B1F Emerald)	MS3-7 Pfizer Japan Inc.	EL3-7-1	EL3-7-2	EL3-7-3		LS3-7 OHARA Pharmaceutical Co., Ltd.					
		No. 8 (B1F Diamond)	MS3-8 Nippon Shinyaku Co., LTD.	O3-8A	O3-8B AML: Clinical 7 Chair : Yoshikazu Ito			LS3-8 Invivoscribe/ LabPMM GK					
Kobe International Conference Center		No. 9 (1F Main Hall)	MS3-9 Recordati Rare Diseases Japan K.K. Medical Affairs	Clinical Debate 1				LS3-9 Johnson & Johnson	Clinical Debate 2				
		No. 10 (3F International Conference Room 301)	MS3-10 Astellas Pharma Inc. Medical Affairs	Symposium 7 Understanding germline findings in the era of genomic medicine Chairs : Emiko Sakaïda, Hideki Muramatsu				LS3-10 Novartis Pharma K.K. Medical Affairs	O3-10C	O3-10D			
		No. 11 (4F 401+402)	MS3-11 Takeda Pharmaceutical Company Limited	O3-11A	O3-11B			LS3-11 Medical Affairs Department, Torii Pharmaceutical Co., Ltd.	O3-11C	O3-11D			
		No. 12 (4F 403)						LS3-12 KM Biologics Co., Ltd./ Japan Blood Products Organization					
		No. 13 (5F 501)	MS3-13 Novartis Pharma K.K. Medical Affairs	O3-13A	O3-13B			LS3-13 Alexion Pharma GK	O3-13C	O3-13D			
		No. 14 (5F 502)	MS3-14 ONO PHARMACEUTICAL CO., LTD.	O3-14A HSCT: GVHD 3 Chair : Kumi Oshima	O3-14B HSCT: Stem Cell Mobilization/AutoSCT/ International Chair : Chikako Ohwada			LS3-14 CSL Behring K.K.	O3-14C	O3-14D			
		No. 15 (5F 504+505)	MS3-15 CSL Behring K.K.	O3-15A	O3-15B			LS3-15 Nippon Becton Dickinson Co., Ltd.	O3-15C	O3-15D			
		No. 16 (3F 3A Meeting Room)	MS3-16 Johnson & Johnson	O3-16A	O3-16B			LS3-16 Genmab K.K. / AbbVie GK	O3-16C	O3-16D			
Kobe International Exhibition Hall	No.2 Building	No. 17 (2F 2A Meeting Room)	MS3-17 GlaxoSmithKline K.K.	O3-17A	O3-17B			LS3-17 Amgen K.K./ Astellas Pharma Inc.	O3-17C	O3-17D Bone Marrow Failure: Basic 2 Chair : Hiroyuki Takamori			
	No.1 Build.	No. 18 (2F Exhibition Hall B)	MS3-18 ASAHI KASEI PHARMA CORPORATION	O3-18A Clinical Trial: Indolent Lymphoma Chair : Masuho Saburi	O3-18B			LS3-18 Nippon Shinyaku Co., Ltd.	O3-18C	O3-18D			
		Poster (No.1 Build. 2F Exhibition Hall A / No.3 Build. 1F Exhibition Hall)	Poster Mounting (8 : 00~11 : 00)			Poster Viewing (11 : 00~13 : 10)			Poster Discussion (13 : 10~14 : 10)				
		8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00